Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease

Respiratory Research

Volumn 7, Issue , 2006, Pages

  Pons, Jaume ^a   Sauleda, Jaume ^a   Regueiro, Verónica ^b   Santos, Carmen ^a   López, Meritxell ^a   Ferrer, Joana ^a   Agustí, Alvar G N ^a,b   Bengoechea, José A ^a,b  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Program Infection and Immunity   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CD14 ANTIGEN; INTERLEUKIN 6; LEVOFLOXACIN; LIPOPOLYSACCHARIDE; METHYLPREDNISOLONE; PEPTIDOGLYCAN; SALBUTAMOL; STEROID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL STIMULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MONOCYTE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION; AGED; BIOSYNTHESIS; CELL CULTURE; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; MONOCYTES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TOLL-LIKE RECEPTOR 2; UP-REGULATION;

EID: 33646508108     PISSN: 1465993X     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-7-64     Document Type: Article

References (46)

1. Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
2. Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
3. Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
4. Agusti AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, Batle S, Busquets X: Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:485-489.
5. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X: Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360.
6. Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002, 347:465-471.
7. White AJ, Gompertz S, Stockley RA: Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003, 58:73-80.
8. Janeway CAJ, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
9. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
10. Van Amersfoort ES, Van Berkel TJ, Kuiper J: Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003, 16:379-414.
11. da Silva CJ, Soldau K, Christen U, Tobias PS, Ulevitch RJ: Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001, 276:21129-21135.
12. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V: Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995, 152:1316-1320.
13. Zalacain R, Sobradillo V, Amilibia J, Barron J, Achotegui V, Pijoan JI, Llorente JL: Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999, 13:343-348.
14. Sethi S, Wrona C, Grant BJ, Murphy TF: Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 169:448-453.
15. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995, 152:1107-1136.
16. Roca J, Sanchis J, Agusti-Vidal A, Segarra F, Navajas D, Rodriguez-Roisin R, Casan P, Sans S: Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir 1986, 22:217-224.
17. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ: Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000, 165:618-622.
18. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, Boneca IG: Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 2004, 5:1000-1006.
19. Deering RP, Orange JS: Development of a clinical assay to evaluate toll-like receptor function. Clin Vaccine Immunol 2006, 13:68-76.
20. Cook DN, Pisetsky DS, Schwartz DA: Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004, 5:975-979.
21. Sabroe I, Whyte MK, Wilson AG, Dower SK, Hubbard R, Hall I: Toll-like receptor (TLR) 4 polymorphisms and COPD. Thorax 2004, 59:81.
22. Bihl F, Salez L, Beaubier M, Torres D, Lariviere L, Laroche L, Benedetto A, Martel D, Lapointe JM, Ryffel B, Malo D: Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol 2003, 170:6141-6150.
23. Kalis C, Kanzler B, Lembo A, Poltorak A, Galanos C, Freudenberg MA: Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur J Immunol 2003, 33:798-805.
24. Akira S: Mammalian Toll-like receptors. Curr Opin Immunol 2003, 15:5-11.
25. Girardin SE, Travassos LH, Herve M, Blanot D, Boneca IG, Philpott DJ, Sansonetti PJ, Mengin-Lecreulx D: Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 2003, 278:41702-41708.
26. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003, 278:8869-8872.
27. Riordan SM, Skinner N, Nagree A, McCallum H, McIver CJ, Kurtovic J, Hamilton JA, Bengmark S, Williams R, Visvanathan K: Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003, 37:1154-1164.
28. Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, Murphy TF, Lim DJ, Li JD: Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha/beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci U S A 2001, 98:8774-8779.
29. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D: Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999, 163:1-5.
30. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, Ouaaz F, Medzhitov RM, Beg AA: An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001, 166:7128-7135.
31. Vabulas RM, Wagner H, Schild H: Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol 2002, 270:169-184.
32. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
33. Shuto T, Imasato A, Jono H, Sakai A, Xu H, Watanabe T, Rixter DD, Kai H, Andalibi A, Linthicum F, Guan YL, Han J, Cato AC, Lim DJ, Akira S, Li JD: Glucocorticoids synergistically enhance non-typeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem 2002, 277:17263-17270.
34. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S: Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:266-272.
35. Matsuguchi T, Musikacharoen T, Ogawa T, Yoshikai Y: Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol 2000, 165:5767-5772.
36. Sabroe I, Jones EC, Usher LR, Whyte MK, Dower SK: Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J Immunol 2002, 168:4701-4710.
37. Noguera A, Busquets X, Sauleda J, Villaverde JM, MacNee W, Agusti AG: Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:1664-1668.
38. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B: Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005, 6:68.
39. Srivastava M, Jung S, Wilhelm J, Fink L, Buhling F, Welte T, Bohle RM, Seeger W, Lohmeyer J, Maus UA: The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. J Immunol 2005, 175:1884-1893.
40. Barnes PJ: New concepts in chronic obstructive pulmonary disease. Annu Rev Med 2003, 54:113-129.
41. Barnes PJ, Ito K, Adcock IM: Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004, 363:731-733.
42. Agusti AG: Systemic effects of chronic obstructive pulmonary disease. Novartis Found Symp 2001, 234:242-249.
43. Wick G, Knoflach M, Xu Q: Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004, 22:361-403.
44. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
45. Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993, 20:259-262.
46. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A: Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001, 108:1781-1788.